Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06756932 · ClinicalTrials.gov registry record · Phase 1
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 16
- Study locations
NCT06756932 is a Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 120 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT06756932, a Phase 1 study of Metastatic Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG BGB-43395
- DRUG BGB-21447
Study Locations (16)
New South Wales
- Saint Vincents Hospital Sydney - Darlinghurst
- Calvary Mater Newcastle - Waratah
Victoria
- Peter Maccallum Cancer Centre - Melbourne
- Western Health Sunshine Hospital - St Albans
California
- Hoag Memorial Presbyterian - Newport Beach
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Texas
- Md Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Queensland
- Sunshine Coast University Private Hospital - Birtinya
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06756932
The ClinicalTrials.gov registry entry for NCT06756932 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT06756932 reports 16 study locations spanning 14 distinct geographic areas - top geographies include New South Wales, Victoria, California.
Frequently Asked Questions
What is clinical trial NCT06756932 about?
NCT06756932 is a clinical study titled "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer". This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast c...
What is the current status of trial NCT06756932?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-02-04. Estimated completion is 2027-07-30.
What conditions does trial NCT06756932 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-Negative Breast Cancer, Hormone Receptor-Positive Breast Cancer.
What interventions are being tested in trial NCT06756932?
The interventions under investigation include: Fulvestrant (DRUG), BGB-43395 (DRUG), BGB-21447 (DRUG).
Who is sponsoring clinical trial NCT06756932?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06756932 being conducted?
This trial has 16 study locations across California, Iowa, Texas, Washington, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.